OncoMetabolic Bridge is a data platform dedicated to integrating high-quality evidence on the links between metabolism, weight-loss surgery, and cancer risk. It aims to provide patients, clinicians, and public health decision-makers with clear, reliable scientific evidence to support personalized choices.
This platform is dedicated to providing high-quality research evidence on the relationship between metabolic surgery and cancer risk, to support decision-making.
The content on this platform does not constitute clinical guidelines and does not substitute for professional medical judgment.
Platform Value
Built to support shared decision-making across clinical teams and people living with obesity.
By integrating data from 72 global meta-analyses covering 21 cancer types and over 210 million individuals, the platform translates complex research findings into visualized risk-benefit profiles. This helps both clinicians and patients jointly assess the potential long-term cancer risks associated with different surgical approaches.
From the initial design phase, the platform incorporated feedback from a multidisciplinary team, including bariatric surgeons, oncologists, epidemiologists, and patients with surgical experience. This ensures that the data presentation aligns with clinical needs while remaining accessible and understandable for patients.
To enhance the platform's practicality and generalizability, we collaborated with over 150 clinical experts from North America, Europe, and Asia, including specialists in bariatric surgery, endocrinology, and oncology, as well as more than 90 patients with metabolic surgery experience. Through iterative surveys and prototype testing, we refined the data visualization and interactive features.
This process ensures that the platform not only supports researchers in exploring macro-level evidence but also helps clinicians quickly identify personalized decision-making resources.
